Related Experiment Video
Updated: Mar 14, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
Contemporary Controversies in Digoxin Use in Systolic Heart Failure
Chonyang L Albert1, Forum Kamdar1, Mazen Hanna2
1Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH, 44195, USA.
Digoxin is an old heart failure treatment with debated safety and efficacy. This review examines its role in modern therapy, focusing on benefits, risks, and optimal use in systolic heart failure.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Digoxin is a long-standing treatment for heart failure.
- Its safety and efficacy have historically been debated.
- Uncertainty persists regarding its role alongside contemporary therapies.
Purpose of the Study:
- To review current data on digoxin use in systolic heart failure.
- To address controversies surrounding digoxin's place in modern heart failure management.
- To discuss optimizing digoxin therapy and minimizing adverse effects.
Main Methods:
- Literature review of recent studies on digoxin in heart failure.
- Analysis of clinical trial data and observational studies.
- Synthesis of evidence regarding efficacy, safety, and patient selection.
Main Results:
- Recent data provide insights into digoxin's efficacy when added to modern heart failure treatments.
- Evidence suggests specific scenarios where digoxin may offer benefits.
- Understanding of digoxin's adverse effect profile continues to evolve.
Conclusions:
- Digoxin's role in systolic heart failure requires careful consideration of contemporary treatment guidelines.
- Further research is needed to clarify optimal patient selection and dosing strategies.
- Balancing potential benefits against risks is crucial for effective digoxin use.
More Related Videos
09:20Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Heart Failure Drugs: Diuretics
Heart Failure VI: Adjunct Therapies
Heart Failure V: Medical Management
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System